Ciclosporin (CsA) and keyhole-limpet hemocyanin (KLH) are potent immunomodulators. Their effects on the induction of bladder carcinoma were investigated in Wistar rats using N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) as a known initiator of bladder carcinoma. In a first series the immunosystem was suppressed by CsA. Rats treated with 0.05% BBN + CsA 5 mg/kg/day or CsA 12.5 mg/kg/day orally developed a CsA dose-dependent (2-to 4-fold) enhancement of bladder tumor expansion as compared to 0.05% BBN application alone. In contrast, immunovariation by stimulation with KLH 12.5 mg i.ves. + 0.5 mg s.c. 2 ×/week after being sensitized with 1 × 1 mg KLH s.c. resulted in a reduction of BBN-induced bladder tumors. The results confirm the immunosurveillance theory that effective expression of immunoresponse may be important in the control of tumor development. The effective immunostimulation by KLH support the concept of immunotherapy in bladder cancer.

Keywords:
Immunosystem, Ciclosporin, Keyhole-limpet hemocyanin, Bladder tumor, N-butyl-N-(4-hydroxybutyl)nitrosamine
This content is only available via PDF.
© 1989 S. Karger AG, Basel
1989
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.